Choose newer migraine agents by matching renal, hepatic, cardiovascular, and adverse-effect constraints rather than treating all CGRP-directed therapies as interchangeable, and document clearly why one option is safer than another.

Rimegepant should be avoided in severe hepatic impairment and end-stage renal disease; Anti-CGRP monoclonal antibodies have minimal classic CYP-mediated drug interactions; Fc receptor recycling helps explain the long half-life of monoclonal antibodies; Lasmiditan carries a higher adverse-event burden than gepants; Ditans and gepants may be safer than triptans when vasoconstriction is a concern